Study of Capecitabine and Irinotecan for Advanced Gastrointestinal Tumors
Author Information
Author(s): Delord J P, Pierga J Y, Dieras V, Bertheault-Cvitkovic F, Turpin F L, Lokiec F, Lochon I, Chatelut E, Canal P, Guimbaud R, Mery-Mignard D, Cornen X, Mouri Z, Bugat R
Primary Institution: Institut Claudius Regaud
Hypothesis
The study aimed to assess the toxicity and pharmacokinetic interactions of capecitabine and irinotecan combination therapy in patients with metastatic gastrointestinal tumors.
Conclusion
The XELIRI regimen is a feasible and clinically active treatment for patients with advanced gastrointestinal cancer.
Supporting Evidence
- The study included 27 patients with advanced gastrointestinal tumors.
- The maximum-tolerated dose was identified as capecitabine 1150 mg/m² twice daily with irinotecan 250 mg/m².
- Complete and partial responses were observed in heavily pretreated patients.
- The combination therapy showed no significant pharmacokinetic interactions.
- Diarrhea and neutropenia were the principal dose-limiting toxicities.
Takeaway
Doctors tested a new medicine combination to help people with stomach cancer, and it worked pretty well without causing too many bad side effects.
Methodology
This was a phase I, open-label, dose-escalation study conducted in three French Cancer Centres.
Potential Biases
Potential bias may arise from the open-label design and the specific selection criteria for participants.
Limitations
The study was limited to a small sample size and specific patient demographics, which may not be generalizable.
Participant Demographics
{"median_age":58,"age_range":"33-72","gender_distribution":{"male":18,"female":9},"primary_tumor_site":{"colorectal":21,"gastric":4,"pancreas":2},"histology":{"adenocarcinoma":26,"squamous_cell_carcinoma":1},"prior_treatment":{"surgery":23,"radiotherapy":6}}
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website